|Table of Contents|

Efficacy of camrelizumab combined with albumin-bound paclitaxel and nedaplatin in the treatment of locally advanced esophageal squamous cell carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 22
Page:
4167-4171
Research Field:
Publishing date:

Info

Title:
Efficacy of camrelizumab combined with albumin-bound paclitaxel and nedaplatin in the treatment of locally advanced esophageal squamous cell carcinoma
Author(s):
LI Xiaolin1; JIN Dayi1; SONG Yingming2
1.The First Clinical College,Changzhi Medical College,Shanxi Changzhi 046000,China；2.Department of Surgical Oncology，Heping Hospital Affiliated to Changzhi Medical College，Shanxi Changzhi 046000,China.
Keywords:
esophageal cancer; camrelizumab; clinical efficacy; albumin-bound paclitaxel; nedaplatin
PACS:
R735.1
DOI:
10.3969/j.issn.1672-4992.2023.22.013
Abstract:
Objective:To explore the clinical efficacy and safety of camrelizumab in combination with albumin-bound paclitaxel and nedaplatin chemotherapy for locally advanced esophageal squamous cell carcinoma.Methods:The clinical data of 60 patients with locally advanced esophageal cancer who underwent radical esophageal cancer resection after receiving neoadjuvant chemotherapy and immunotherapy plus chemotherapy in Heping Hospital Affiliated to Changzhi Medical College from July 2019 to July 2022 were retrospectively analyzed.Patients were divided into observation group and control group according to the treatment strategy.30 patients in the control group were treated with neoadjuvant chemotherapy(albumin-bound paclitaxel+nedaplatin).30 patients in the observation group were treated with immunotherapy combined with neoadjuvant chemotherapy (camrelizumab+albumin-bound paclitaxel+nedaplatin).The recent efficacy,the incidence of adverse reactions related to chemotherapy and immunotherapy,and the rate of pathologic complete response after neoadjuvant therapy in the two groups were compared.Results:The objective response rate (ORR) (80.0%) was higher in the observation group than the control group (43.3%),and the difference was statistically significant （P＜0.05）.The difference in disease control rate (DCR) between the two groups was not statistically significant (100.0% vs 90.0%,P＞0.05）.With the exception of the immune-related adverse reaction,reactive cutaneous capillary endothelial proliferation (RCCEP),the difference in the incidence of adverse reactions between the observation and control groups was not statistically significant (P>0.05).Most of the adverse reactions were grade 1 to 2 and did not affect the chemotherapy process or the surgery.The pathologic complete response (pCR) (40.0%) was higher in the observation group than in the control group (6.7%),and the difference was statistically significant (P＜0.05).Conclusion:Camrelizumab in combination with albumin-bound paclitaxel and nedaplatin can significantly improve pathologic complete response rate for locally advanced esophageal squamous cell carcinoma patients with promising antitumor activity and a manageable safety.

References:

[1] SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
[2] SIHAG S,KU GY,TAN KS,et al.Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer［J］.J Thorac Cardiovasc Surg,2021,161(3):836-843.
[3] KELLY RJ.Immunotherapy for esophageal and gastric cancer［J］.Am Soc Clin Oncol Educ Book,2017,37:292-300.
[4] LUO H,LU J,BAI Y,et al.Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma:the ESCORT-1st randomized clinical trial［J］.Jama,2021,326(10):916-925.
[5] QIAO Y,ZHAO C,LI X,et al.Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy［J］.Front Immunol,2022,13:953229.
[6] YIN GQ,LI ZL,LI D.The safety and efficacy of neoadjuvant camrelizumab plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma:a retrospective study［J］.Cancer Manag Res,2022,14:2133-2141.
[7] KOSHIYAMA M,KINEZAKI M,UCHIDA T,et al.Chemosensitivity testing of a novel platinum analog,nedaplatin (254-S),in human gynecological carcinomas:a comparison with cisplatin［J］.Anticancer Res,2005,25(6c):4499-4502.
[8] FU Q,SUN J,ZHANG W,et al.Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery［J］.Recent Pat Anticancer Drug Discov,2009,4(3):262-272.
[9] SCHWARTZ LH,LITIRE S,DE VRIES E,et al.RECIST 1.1-update and clarification:from the RECIST committee［J］.Eur J Cancer,2016,62:132-137.
[10] FREITES-MARTINEZ A,SANTANA N,ARIAS-SANTIAGO S,et al.Using the Common Terminology Criteria for Adverse Events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies［J］.Actas Dermosifiliogr (Engl Ed),2021,112(1):90-92.
[11] LAGERGREN J,SMYTH E,CUNNINGHAM D,et al.Oesophageal cancer［J］.Lancet,2017,390(10110):2383-2396.
[12] PASQUALI S,YIM G,VOHRA RS,et al.Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma:a network Meta-analysis［J］.Ann Surg,2017,265(3):481-491.
[13] 李娇，王鑫.局部晚期食管癌新辅助治疗的研究进展［J］.现代肿瘤医学，2023,31（05）：955-960. LI Jiao,WANG Xin.Research progress of neoadjuvant therapy for local advanced esophageal cancer［J］.Modern Oncology,2023,31（05）：955-960.
[14] TEN TIJE AJ,VERWEIJ J,LOOS WJ,et al.Pharmacological effects of formulation vehicles:implications for cancer chemotherapy［J］.Clin Pharmacokinet,2003,42(7):665-685.
[15] WANG Y,LI L,XU C.Nanoparticle albumin bound paclitaxel in the third-line treatment of recurrent small cell lung cancer in real-world practice:a single center experience［J］.Technol Cancer Res Treat,2021,20:15330338211050775.
[16] LITTERMAN AJ,DUDEK AZ,LARGAESPADA DA.Alkylating chemotherapy may exert a uniquely deleterious effect upon neo-antigen-targeting anticancer vaccination［J］.Oncoimmunology,2013,2(10):e26294.
[17] YARCHOAN M,JOHNSON BA,LUTZ ER,et al.Targeting neoantigens to augment antitumour immunity［J］.Nat Rev Cancer,2017,17(4):209-222.
[18] ZHANG Y,CHEN M,CHEN C,et al.The efficacy and toxicities of intensive induction chemotherapy followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma patients with N(3) disease［J］.Sci Rep,2017,7(1):3668.
[19] SJOQUIST KM,BURMEISTER BH,SMITHERS BM,et al.Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma:an updated meta-analysis［J］.Lancet Oncol,2011,12(7):681-692.
[20] TANAKA T,NAKAMURA J,NOSHIRO H.Promising immunotherapies for esophageal cancer［J］.Expert Opin Biol Ther,2017,17(6):723-733.
[21] SALMANINEJAD A,KHORAMSHAHI V,AZANI A,et al.PD-1 and cancer:molecular mechanisms and polymorphisms［J］.Immunogenetics,2018,70(2):73-86.
[22] SONG H,LIU X,JIANG L,et al.Current status and prospects of camrelizumab,a humanized antibody against programmed cell death receptor 1［J］.Recent Pat Anticancer Drug Discov,2021,16(3):312-332.
[23] GAO TT,SHAN JH,YANG YX,et al.Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma:a systematic review and network Meta-analysis［J］.BMC Cancer,2022,22(1):992.
[24] CHEN G,LA EMENS.Chemoimmunotherapy:reengineering tumor immunity［J］.Cancer Immunol Immunother,2013,62(2):203-216.
[25] WU Z,ZHENG Q,CHEN H,et al.Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma［J］.J Thorac Dis,2021,13(6):3518-3528.
[26] HUANG J,XU J,CHEN Y,et al.Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT):a multicentre,randomised,open-label,phase 3 study［J］.Lancet Oncol,2020,21(6):832-842.
[27] SONG G,ZHANG FF,CHENG HD.Thalidomide for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation［J］.Australas J Dermatol,2022,63(2):217-221.
[28] LI Q,CAO M,YUAN G,et al.Lenvatinib plus camrelizumab vs.lenvatinib monotherapy as first-line treatment for unresectable hepatocellular carcinoma:a multicenter retrospective cohort study［J］.Front Oncol,2022,12:809709.

Memo

Memo:
2022年山西省高等学校大学生创新创业训练计划项目(编号：20220840)
Last Update: 1900-01-01